ArticleFrontiers in medicine2026
Case Report: Five-year follow-up of leptomeningeal transthyretin amyloidosis (Ala45Thr) with CNS involvement under tolcapone therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transthyretin (TTR) p.Ala45Thr variant is pathogenic, typically associated with cardiomyopathy and peripheral neuropathy. Leptomeningeal and central nervous system (CNS) involvement is rare, and longitudinal treatment data remain limited. Methods: We conducted a single-patient longitudinal observational study of a patient with genetically confirmed hereditary transthyretin amyloidosis (ATTRv) carrying the Results: A 48-year-old woman presented with progressive neurological symptoms beginning at age 37, including gait ataxia, dysarthria, and left hypoesthesia. Family history was notable for early-onset neurological decline in maternal relatives. Baseline MRI showed cerebellar micro-hemorrhages, leptomeningeal enhancement, and a cervical spinal cord lesion (C4-C7). CSF protein was markedly elevated, and genetic testing confirmed the TTR p.Ala45Thr variant. Cardiac and peripheral nerve evaluations were unremarkable. Tolcapone therapy was initiated and titrated to the maximal dose. Over 5 years, follow-up assessments demonstrated progressive neurological and cognitive decline, increased CSF protein levels, and enlargement of the spinal cord lesion, with mild progression of leptomeningeal and ependymal enhancement on MRI. Conclusion: This report highlights progressive CNS involvement in Ala45Thr-associated ATTR despite treatment with a CNS-penetrant TTR stabilizer. These findings suggest that disease progression may continue despite TTR stabilization in some patients and underscore the need for early intervention, systematic CNS monitoring, and further development of CNS-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.